Home Healthcare Car T Cell Therapy Market
car t cell therapy market

CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen (CD19/CD22, BCMA, Others); By Indication (Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma (FL), Others); By Region: Segment Forecast, 2022 – 2029

  • Published Date: Jan 2022
  • Pages: 108
  • Format: PDF
  • Report ID: PM1389
  • Base Year: 2021
  • Historical Data: 2017-2020

Report Summary

The global CAR-T cell therapy market was valued at USD 1,965.8 million in 2021, expected to grow at a CAGR of 31.16 % during the forecast period. CAR-T therapy is a sort of treatment in which a patient's T cells which is a type of immune system cell, are genetically modified to attack cancer cells in the lab. T cells are extracted from the blood of a patient. The gene for a specific receptor that binds to a specific protein on the patient's cancer cells is then transferred to T cells in the lab.

U.S. CAR-T Cell Therapy Market SizeKnow more about this reportrequest for sample pages 

A chimeric antigen receptor is a unique type of receptor (CAR). CAR-T units are generated in large numbers in the lab and then infused into the patient. CAR-T therapy is used to treat specific types of blood malignancies, and it is also being researched for other cancers. CAR T therapy is also known as Chimeric antigen receptor T-cell therapy. T cells are used in CAR T therapy since they are generally responsible for destroying malignant cells and virus-infected cells. Cancer cells are known to hide from the immune system, but scientists have been able to improve T cells' ability to locate and kill cancer cells using CAR T therapy.

The COVID-19 lockdown resulted in supply chain disruptions and the interruption of company operations, leaving many life science and biopharma businesses waiting for new batches of raw material for CAR T unit manufacture. During COVID-19, outbreak lockdown was imposed in many regions, which disrupted the supply chain and discontinued business operations leaving many life science and biopharma businesses waiting for new batches of raw material for CAR T cell manufacture.

Market Dynamics

Growth Drivers
CAR T therapy market is expected to grow due to the growing prevalence of cancer cases across the globe. This treatment has captured the attention of researchers and the public because of the remarkable responses they have produced in patients. The Food and Drug Administration (FDA) approved two CAR T treatments in 2017, one for children with acute lymphoblastic leukaemia (ALL) and the other for adults with advanced lymphomas.

Continuous growth has been witnessed in biotechnology and life science sectors for the treatment of cancer using chimeric antigen receptors. Increased patient assistance programs (PAPs), increased government activities for cancer awareness, rising cancer prevalence worldwide, and strong R&D initiatives from key companies are all driving CAR-T cell therapy market expansion. With the growing need for cell-based therapy, producers have started investing in the manufacturing of this therapy.

Report Segmentation

The market is primarily segmented on the basis of the target antigen, indication, and region.

By Target Antigen

By Indication

By Region

  • CD19/CD22
  • BCMA (B-Cell Maturation Antigen)
  • Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13Ra2, LewisY)
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Acute Lymphoblastic Leukemia (ALL)
  • Chronic Lymphocytic Leukemia (CLL)
  • Multiple Myeloma (MM)
  • Follicular Lymphoma (FL)
  • Others
  • North America (U.S., Canada)
  • Europe (Germany, France, Switzerland)
  • Asia Pacific (China, Japan)
  • Rest of World

Know more about this reportrequest for sample pages

Insight By Indication

It is estimated that the market for DLBCL holds the highest market share and is CAR-T estimated to grow during the forecast period. Diffuse large B-cell lymphoma (DLBCL) is a cancer of the lymphatic system, which is an essential aspect of the immune system. Blood units that create antibodies to fight infections are affected. Chimeric antigen receptor' CAR-T treatment is a promising treatment for DLBCL.

Geographic Overview

North America is expected to dominate the global CAR-T cell therapy market due to the increasing cancer cases and growing emergence of the biotechnological sector. North America is witnessing an increasing number of cancer cases which is increasing the market demand for cancer therapies in the region. With the presence of key players in the region such as Amgen Inc., Bellicum Pharmaceuticals, Inc., Bluebird Bio, Caribou Biosciences, Inc., which are focusing on expanding their global presence, is fuelling the CAR-T cell therapy market.

The CAR-T treatment industry will develop at a high rate as a result of shifting patterns in the European market and the growing usage of appropriate technologies. With the Kymriah and Yescarta, the first medicines supported through EMA's PRIority MEdicines (PRIME) scheme received positive opinions from the Committee for Medicinal Products for Human Use (CHMP), due to which the CAR-T market is expected to boost.

Kymriah is indicated for the treatment of relapsed or refractory B-cell ALL in pediatric and young adult patients (up to 25 years of age), as well as adult patients with relapsed or refractory DLBCL after two or more lines of systemic treatment.

After two or more lines of systemic treatment, Yescarta is indicated for the treatment of adult patients with relapsed or refractory DLBCL and primary mediastinal large B-cell lymphoma (PMBCL).

Competitive Landscape

Some major players in the global market include Amgen Inc. (US), Bellicum Pharmaceuticals, Inc. (US), Bluebird Bio (US), Caribou Biosciences, Inc. (US), Celgene Corporation, Cellectis, Celyad, Gilead Sciences, Inc., Intellia Therapeutics, Johnson & Johnson, Mereck KGaA, Nanjing Legend Biotechnology Co., Ltd., Noile-Immune Biotech, Novartis International AG, Pfizer Inc., Sangamo Therapeutics, Inc., Servier Laboratories.

Biotech and pharmaceutical businesses are working on mergers, acquisitions, and advancing technology to gain a competitive advantage in this industry. For Instance, Novartis announces T-Charge™, a next-generation CAR-T platform with first-in-human data at ASH 2021 that aims to transform CAR-T treatment and will serve as a foundation for a variety of experimental CAR-T therapies.

In December 2017, Gilead Sciences, Inc. and its cell therapy subsidiary Kite announced that they have signed a definitive agreement to acquire Cell Design Labs, Inc., gaining new technology platforms that will help them advance their cellular treatment research and development initiatives.

CAR-T Cell Therapy Market Report Scope

Report Attributes

Details

Market size value in 2021

USD 1,965.8 million

Revenue forecast in 2029

USD 20,566.5 million

CAGR

31.6% from 2022 - 2029

Base year

2021

Historical data

2017 - 2020

Forecast period

2022 - 2029

Quantitative units

Revenue in USD million and CAGR from 2021 to 2029

Segments covered

By Target Antigen, By Indication, By Region

Regional scope

North America, Europe, Asia Pacific, Rest of World

Key Companies

Amgen Inc. (US), Bellicum Pharmaceuticals, Inc. (US), Bluebird Bio (US), Caribou Biosciences, Inc. (US), Celgene Corporation, Cellectis, Celyad, Gilead Sciences, Inc., Intellia Therapeutics, Johnson & Johnson, Mereck KGaA, Nanjing Legend Biotechnology Co., Ltd., Noile-Immune Biotech, Novartis International AG, Pfizer Inc., Sangamo Therapeutics, Inc., Servier Laboratories.

Key Take-Away
Polaris Market Research
CAR-T Cell Therapy Market | 2022-29 | Share, Size, Industry Report